Sugi Predict

Sugi Predict / Compounds / SCHEMBL834706

SCHEMBL834706

SCHEMBL834706

Oc1c(Cl)ccc2c1CCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 5/20 0.43
▸ BCL2L1 Q07817 1/20 0.42
▸ BAD Q92934 1/20 0.42
▸ HTR2A P28223 2/20 0.38
▸ HTR2C P28335 2/20 0.38
▸ HTR2B P41595 2/20 0.38
▸ ADRA2A P08913 1/20 0.37
▸ ADRA2B P18089 1/20 0.37
▸ ADRA2C P18825 1/20 0.37
▸ PARP1 P09874 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ MPI P34949 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22632718 0.86 HTR2A (0.41) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL10227459 0.78 HTR2A (0.67) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL11322190 0.77 PNMT (0.70) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL1535927 0.77 BCL2L1 (0.50) BCL2L1BAD
SCHEMBL835826 0.76 BCL2L1 (0.43) BCL2L1BADPARP1KDM4EMEN1
SCHEMBL24133294 0.74 BCL2L1 (0.42) BCL2L1BADHTR2AHTR2CHTR2B
SCHEMBL22103240 0.74 PNMT (0.47) PNMTBCL2L1BADHTR2AHTR2C
SCHEMBL22102574 0.74 PNMT (0.43) PNMTBCL2L1BADHTR2AHTR2C
SCHEMBL22990006 0.74 PNMT (0.43) PNMTBCL2L1BADHTR2AHTR2C
SCHEMBL15471189 0.74 PNMT (0.43) PNMTHTR2AHTR2CHTR2BADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112105610-B Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation 朱比连特普罗德尔有限责任公司 2024-01-26 — — CN disclosed
US-20230257367-A1 NOVEL THYROID HORMONE BETA RECEPTOR AGONIST CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) 2023-08-17 — — US disclosed
US-20230257367-A1 NOVEL THYROID HORMONE BETA RECEPTOR AGONIST CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) 2023-08-17 — — US disclosed
EP-4159723-A1 NOVEL THYROID HORMONE ß RECEPTOR AGONIST Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) 2023-04-05 — — EP disclosed
US-11529341-B2 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation Jubilant Prodel LLC 2022-12-20 — — US disclosed
US-11529341-B2 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation Jubilant Prodel LLC 2022-12-20 — — US disclosed
US-20210115022-A1 THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2021-04-22 — — US disclosed
US-20210015810-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION Jubilant Prodel LLC 2021-01-21 — — US disclosed
US-20210015810-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION Jubilant Prodel LLC 2021-01-21 — — US disclosed
EP-3765453-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION Jubilant Prodel LLC (US) 2021-01-20 — — EP disclosed
EP-2061766-B1 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS LTD (IN) 2010-08-18 — — EP disclosed
US-20100168110-A1 Novel Compounds TORRENT PHARMACEUTICALS LTD. (IN) 2010-07-01 — — US disclosed
EP-2061766-A2 NOVEL COMPOUNDS Torrent Pharmaceuticals Ltd (IN) 2009-05-27 — — EP disclosed
WO-2008149379-A2 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS LTD. (IN) 2008-12-11 — — WO disclosed
EP-0863136-B1 Derivatives of azetidine and pyrrolidine AKZO NOBEL NV (NL) 2003-09-24 — — EP disclosed
US-6403573-B1 BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES AKZO NOBEL N.V. (NL) 2002-06-11 — — US disclosed
US-20020040016-A1 Derivatives of azetidine and pyrrolidine MERCK SHARP & DOHME B.V. (NL) 2002-04-04 — — US disclosed
US-6281243-B1 ANTIDEPRESSANTS, ANTISEROTONINE AGENT AKZO NOBEL N.V. (NL) 2001-08-28 — — US disclosed
WO-1999043647-A1 DERIVATIVES OF AZETIDINE AND PYRROLIDINE AKZO NOBEL N.V. (NL) 1999-09-02 — — WO disclosed
EP-0863136-A1 Derivatives of azetidine and pyrrolidine Akzo Nobel N.V. (NL) 1998-09-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115022-A1 THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF TSHR, THRA, TRHR PNMT 1934/4885BCL2L1 4794/4885BAD 1352/4885
US-20210015810-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION CD274, PDCD1, PDCD1LG2 PNMT 4545/4885BCL2L1 349/4885BAD 49/4885
US-20020040016-A1 Derivatives of azetidine and pyrrolidine TPH1, TPH2, HTR1D PNMT 76/4885BCL2L1 1937/4885BAD 1150/4885
US-20230257367-A1 NOVEL THYROID HORMONE BETA RECEPTOR AGONIST THRB, THRA, TSHR PNMT 3926/4885BCL2L1 3704/4885BAD 685/4885
US-20100168110-A1 Novel Compounds TSHR, THRB, GPR119 PNMT 2153/4885BCL2L1 3358/4885BAD 3146/4885
US-11529341-B2 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation CD274, PDCD1, PDCD1LG2 PNMT 4545/4885BCL2L1 349/4885BAD 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.